Company news from the 10/17/06 News Brief

Share this article:
Boehringer Ingelheim said it would purchase the US marketing rights to heartburn drug Zantac for $509.5 million as part of Pfizer’s sale of its consumer unit to Johnson & Johnson. In a statement about the purchase, Boehringer Ingelheim Corp. president and CEO J. Martin Carroll said Zantac, an OTC drug, complements the firm’s existing nonprescription franchise, which includes laxative Dulcolax. Zantac will be distributed through the same retail channels as the Dulcolax business, which will allow for increased promotion and marketing efficiencies, Carroll said. Pfizer is selling Zantac to help facilitate FTC approval of the planned, $16.6 billion sale of its Consumer Healthcare business to J&J, a deal expected to close by year’s end. Boehringer Ingelheim GmbH is the world’s biggest closely held drugmaker.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters